Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Sacituzumab Govitecan Plus Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma
NCT06682728Phase 2Recruiting
- Sponsor
- University of California, Irvine
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in urothelial carcinoma (UC), sponsored by University of California, Irvine. Primary endpoint: Primary Objective. Started Nov 2024; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06682728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682728.